[Current approaches to treatment of secondary sulfonylamide drug resistance in Type II diabetes mellitus].
A differentiated approach toward treating secondary sulfanilamide resistance in patients with type II diabetes and proposed therapeutic regimens simple enough to be adopted in the management of the patients in question permit achieving satisfactory hypoglycemic effect maintaining an acceptable level of glucose in the blood.
Gendeleka
G F
GF
D020909:Acarbose / Q000097:blood / Q000627:therapeutic use; D001786:Blood Glucose / Q000032:analysis; D002220:Carbamazepine / Q000097:blood / Q000627:therapeutic use; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000378:metabolism; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007328:Insulin / Q000097:blood / Q000627:therapeutic use; D008687:Metformin / Q000097:blood / Q000627:therapeutic use; D013424:Sulfanilamides / Q000494:pharmacology / Q000627:therapeutic use*
D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin; D013424:Sulfanilamides; D002220:Carbamazepine; D008687:Metformin; D020909:Acarbose
Sovremennye podkhody k lecheniiu vtorichnoĭ sul'fanilamidnoĭ rezistentnosti pri sakharnom diabete II tipa.